Strengthening Global Health Economics through BRICS Health & Pharmaceutical Association of Africa

By João L. Carapinha

July 12, 2023

We are ecstatic to discuss the recent establishment of the BRICS Health and Pharmaceutical Association for Africa (BRICS-HPAA). According to China Daily and HealthCare Middle East & Africa Magazine, this initiative is a significant step toward improving health systems across the African continent and bracing for future pandemics.

Launched in South Africa, the BRICS-HPAA seeks to utilize research, development, and advanced technology from BRICS nations (Brazil, Russia, India, China, and South Africa) to combat the disease burden in Africa. The association, comprised of members from various African nations and the private sectors of all BRICS nations, seeks to enhance the utilization of traditional medicine with help from China and India, which are already highly developed in this area.

Hilton Klein, chairman and chief executive officer of the Numolux Group, which founded the association, emphasized the importance of vaccine manufacturing, traditional medicine, and innovation hubs for research and development initiatives in Africa. He stated, “We look forward to collaborating with BRICS nations to manufacture capabilities in South Africa, in particular, to serve the rest of the African continent. We will collaborate with the New Development Bank of BRICS to make affordable, high-quality medicines, pharmaceuticals, and medical devices available to all BRICS-aligned nations, preferably in their respective national currencies.”

In order to eradicate disease and pandemics in Africa and BRICS-aligned countries, the association also intends to put up an mRNA and traditional vaccine manufacturing factory. This initiative will facilitate partnerships between African and BRICS companies in R&D, the creation of vaccine manufacturing facilities, and the exchange of knowledge and experiences.

Nomantu Nkomo-Ralehoko, a member of the Executive Council for Health in the South African province of Gauteng, praised Numolux’s initiative. She stated, “We are committed to strengthening relations with African countries and BRICS partners. We need to bring in BRICS countries because they are key in terms of the work we want to do in the areas of pharmaceuticals.”

The BRICS nations, comprising 40% of the worldwide population and a quarter of the globe’s GDP, use a hybrid public-private model for financing and providing healthcare. This partnership between Africa and BRICS could help attain universal health coverage by utilizing their knowledge and technology.

The establishment of the BRICS-HPAA demonstrates the effectiveness of multilateral cooperation in healthcare. We can strive toward a healthier future for all by utilizing the strengths of every individual in our nation. Syenza, as leaders in health economics and outcomes research, we are eager to observe the advancements that this organization will unquestionably make in the coming years.

Reference url

Recent Posts

Zimislecel type 1 diabetes
   

Cell Therapy for Type 1 Diabetes: Vertex Trial Results and Market Potential

🚀 What if we could revolutionize Type 1 diabetes treatment?

Vertex Pharmaceuticals has made significant strides with its promising phase 1/2 trial results for **zimislecel**, a stem cell-derived therapy that not only restores insulin production but also drastically reduces severe hypoglycemic events. As phase 3 trials commence, this breakthrough could reshape care for T1D patients and potentially reduce long-term healthcare costs.

Curious to learn how zimislecel and other potential cell therapies may redefine diabetes management? Click to read more!

#SyenzaNews #biotechnology #HealthEconomics

biosimilar clinical approach
    

Biosimilar Clinical Approach

🚀 How is the EMA’s new biosimilar clinical approach changing the landscape of drug approvals in Europe?

With a focus on tailored clinical assessments, the EMA is streamlining the pathway for biosimilars by allowing analytical data to take precedence over large-scale comparative efficacy studies. This shift promises to enhance patient access to life-saving therapies while maintaining rigorous safety standards.

Dive deeper into the implications of this innovative regulatory approach and find out how it can impact health economics and market access.

👉 Read more in the full article!
#SyenzaNews #regulatoryaffairs #MarketAccess

HIV prevention injection
   

FDA Approval and Access Strategy for Lenacapavir (Yeztugo) Long-Acting HIV Prevention

🌍 Will Yeztugo Approval and Access Strategy Deliver an Inflection Point in HIV/AIDS?

Yeztugo (lenacapavir), a twice-yearly injection, redefines long-acting HIV prevention with 96–100% efficacy. Gilead’s access strategy—insurance, assistance, and generics for 120 countries—targets global impact. Can it balance $28,218 U.S. costs with equity for 1.3M annual infections? My article explores health economics, public health, and market dynamics.

📖 Read how Yeztugo’s access strategy could transform long-acting HIV prevention

#SyenzaNews #GlobalHealth #HIVPrevention #Yeztugo #PrEP

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.